JP2019527729A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527729A5
JP2019527729A5 JP2019522614A JP2019522614A JP2019527729A5 JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5 JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5
Authority
JP
Japan
Prior art keywords
formulation
polypropylene glycol
therapeutic
ppm
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041691 external-priority patent/WO2018013673A1/en
Publication of JP2019527729A publication Critical patent/JP2019527729A/ja
Publication of JP2019527729A5 publication Critical patent/JP2019527729A5/ja
Pending legal-status Critical Current

Links

JP2019522614A 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤 Pending JP2019527729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361793P 2016-07-13 2016-07-13
US62/361,793 2016-07-13
PCT/US2017/041691 WO2018013673A1 (en) 2016-07-13 2017-07-12 Stabilizing excipients for therapeutic protein formulations

Publications (2)

Publication Number Publication Date
JP2019527729A JP2019527729A (ja) 2019-10-03
JP2019527729A5 true JP2019527729A5 (cg-RX-API-DMAC7.html) 2020-08-06

Family

ID=60941865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522614A Pending JP2019527729A (ja) 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤

Country Status (6)

Country Link
US (4) US10279048B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484520A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019527729A (cg-RX-API-DMAC7.html)
KR (1) KR20190027878A (cg-RX-API-DMAC7.html)
CA (1) CA3030422C (cg-RX-API-DMAC7.html)
WO (1) WO2018013673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173338A1 (en) * 2018-03-07 2019-09-12 Reform Biologics, Llc Excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
WO2019180561A1 (en) 2018-03-20 2019-09-26 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
WO2020061414A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
CN112969450B (zh) 2018-09-20 2023-05-30 阿卡蒂亚药品公司 卡贝缩宫素药物产品及用于制备其的方法
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
WO2020213682A1 (ja) * 2019-04-19 2020-10-22 富士フイルム和光純薬株式会社 細胞外小胞の保存安定化剤及び保存安定化方法
EP4178529A1 (en) * 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative surfactants as stabilizers for therapeutic protein formulations
WO2023203257A1 (en) * 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510633C3 (de) 1975-03-12 1978-07-13 Boehringer Mannheim Gmbh, 6800 Mannheim Diagnostisches Mittel zum Nachweis von Eiweiß in Körperflüssigkeiten und dafür geeignete Indikatorfarbstoffe
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US6039977A (en) * 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
AU2002304784A1 (en) * 2001-03-26 2002-10-08 Novartis Pharma Gmbh Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
US7041088B2 (en) 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
DE10325198B4 (de) 2003-06-04 2007-10-25 Clariant Produkte (Deutschland) Gmbh Verwendung von alkoxylierten vernetzten Polyglycerinen als biologisch abbaubare Emulsionsspalter
US8025915B2 (en) 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
JP5081976B2 (ja) 2007-10-22 2012-11-28 ベクトン・ディキンソン・アンド・カンパニー オルガノポリシロキサンを含む懸濁液においてタンパク質の凝集を評価するための方法
CN101795680A (zh) 2007-11-16 2010-08-04 波苏蛋白试剂公司 稳定蛋白质的辅剂
KR20120089843A (ko) * 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
MX344732B (es) * 2010-04-27 2017-01-04 Scil Tech Gmbh Formulacion estable de mia/cd-rap.
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
KR102058307B1 (ko) 2010-06-24 2019-12-20 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
SG10201701634PA (en) * 2011-03-25 2017-04-27 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
EP2855502B1 (en) 2012-05-31 2019-06-26 Agency For Science, Technology And Research Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
JP2015526471A (ja) * 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2926834A4 (en) 2012-11-27 2016-04-20 Alteogen Inc COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED
WO2014151705A1 (en) 2013-03-15 2014-09-25 Ansun Biopharma, Inc. Methods for preparing injectable protein microparticle suspensions
WO2014173886A1 (en) * 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Similar Documents

Publication Publication Date Title
JP2019527729A5 (cg-RX-API-DMAC7.html)
EP2525787B1 (en) Liquid formulations for long-acting g-csf conjugate
Rajoria et al. In-situ gelling system: a novel approach for ocular drug delivery
US9682149B2 (en) Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
JP2016530321A5 (ja) イオン性液体を含有する注射用液状タンパク質製剤およびその使用
KR20140091707A (ko) 크실리톨로 안정화된 에타너셉트 제형
JP7223712B2 (ja) 安定なペプチド組成物
KR20190027878A (ko) 치료 단백질 제제용 안정화 부형제
CN104159614A (zh) TNF-α抗体的药物制剂
US20160120946A1 (en) Compositions comprising gc-macrophage activating factor and uses thereof
JP2010531340A (ja) 新規処方物
JP2019525951A5 (cg-RX-API-DMAC7.html)
JP2019532949A (ja) 耐熱保護剤、室温で保存可能な豚コレラ生ワクチンの製造方法及びその使用
MX2015005230A (es) Composicion farmaceutica estable de peginterferon alfa-2b.
EP4003290B1 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
JPWO2000000221A1 (ja) 水溶性乾燥組成物
CN105412942A (zh) 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN115518151A (zh) 一种人类免疫缺陷病毒中和抗体制剂及其用途
US11229702B1 (en) High concentration formulations of adalimumab
CN101376022A (zh) 含聚乙二醇降纤酶的药物组合物
WO1999045953A1 (fr) Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation
CN110799188A (zh) 基于托品酰胺的眼用制剂
HK1175721A (en) Liquid formulations for long-acting g-csf conjugate
JPWO2014115882A1 (ja) タンパク質を安定化させたゲル状製剤
JPH07242562A (ja) 顆粒球コロニー刺激因子含有直腸投与製剤